Core Insights - Femasys Inc. will showcase its innovative fertility solutions at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas from October 25-29 [1][4] - The company is highlighting its next-generation artificial insemination solution, FemaSeed, which has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count [2][5] - Femasys has expanded its FemaSeed portfolio to include various kits that enable gynecologists to perform sperm preparation and offer FemaSeed directly in their practices [3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally [5] - The company has a patent-protected portfolio of therapeutic and diagnostic products, including FemaSeed and FemVue, aimed at improving reproductive health [5] - Femasys has received regulatory approvals for its products in multiple regions, including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand [2][6] Product Highlights - FemaSeed is positioned as a safe, accessible, and cost-effective alternative to IUI, particularly for patients with low male sperm count [2] - The FemBloc product, a non-surgical permanent birth control solution, received full regulatory approval in Europe, the UK, and New Zealand in 2025 [6] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success for FemBloc [6]

Prevalence and Impact of Male Infertility - The worldwide in vitro fertilization (IVF) market is expected to reach $374 billion in 2030 [3] - Approximately one in five couples worldwide experience infertility [4] - Male infertility accounts for roughly 50% of all infertility cases [4] - For a normal fertile man, sperm counts are equal or greater to 40 million sperm per ejaculate [9] - Only 00001% of all sperm actually reach the final destination to fertilize the egg [10] Challenges and Stigma - Awareness and open conversation about male infertility have remained stagnant despite its increasing commonality [5] - Males who are unable to impregnate their partner often experience feelings of inadequacy and shame, impacting their self-worth and self-esteem [7] - Stigma behind infertility often prevents men from seeking diagnosis and treatment [21][28] Potential Treatment Options and Research - Current treatment options, such as Ixie and microtessy, only treat about 50% of patients [16] - For patients that don't produce any sperm, there are no treatment options to currently treat their infertility [16][21] - Research is being conducted to develop new therapies, including stem cell-based approaches to create immature sperm-like cells or transplantable testice cells [22][23][25] - Immature sperm-like cells have been shown to fertilize a monkey egg and produce healthy monkey embryos [23] Actionable Steps - Encourage open conversation to destigmatize male infertility [28][29] - Consider adding a fertility specialist to annual checkups [29] - Adopt lifestyle changes to avoid exposures that impact fertility [29] - Champion causes that seek to expand treatments for male infertility [30]

Core Viewpoint - The A-share market experienced a collective decline on the last trading day of the month, with significant drops across major indices and a notable increase in trading volume [2] Market Performance - The Shanghai Composite Index fell by 1.18% - The Shenzhen Component Index decreased by 1.73% - The ChiNext Index dropped by 1.66% - The North Star 50 Index declined by 1.16% - Total trading volume in the Shanghai and Shenzhen markets reached 19,618 billion yuan, an increase of 909 billion yuan compared to the previous day [2] Sector Performance - The AI sector, liquid cooling server sector, and assisted reproductive technology sector showed strength, with several stocks hitting the daily limit - The steel, coal, and insurance sectors faced adjustments, with significant declines in stock prices [2] Notable Stocks - In the AI sector, Yidian Tianxia reached the daily limit with a 20% increase - The liquid cooling server sector saw strong performance, with Sihua New Materials also hitting the daily limit - In the assisted reproductive technology sector, Gongtong Pharmaceutical and Anke Bio both reached the daily limit [2] Declines in Specific Sectors - The steel sector experienced a downturn, with Baogang Co. falling over 8% - The coal sector saw a comprehensive decline, with all stocks in the sector showing negative performance, including Antai Group which dropped over 7% [2]